Literature DB >> 22906651

Prostatic fibrosis is associated with lower urinary tract symptoms.

Jinjin Ma1, Mehrnaz Gharaee-Kermani, Lakshmi Kunju, John M Hollingsworth, Jeremy Adler, Ellen M Arruda, Jill A Macoska.   

Abstract

PURPOSE: Current therapies for male lower urinary tract symptoms secondary to prostate enlargement prevent hormonal effects on prostate growth and inhibit smooth muscle contraction to ease bladder neck and urethral pressure. However, lower urinary tract symptoms can be refractory to these therapies, suggesting that additional biological processes not addressed by them may also contribute to lower urinary tract symptoms. Aging associated fibrotic changes in tissue architecture contribute to dysfunction in multiple organ systems. Thus, we tested whether such changes potentially have a role in impaired urethral function and perhaps in male lower urinary tract symptoms.
MATERIALS AND METHODS: Periurethral tissues were obtained from a whole prostate ex vivo and from 28 consecutive men treated with radical prostatectomy. Lower urinary tract symptoms were assessed using the American Urological Association symptom index. Prostate tissues were subjected to mechanical testing to assess rigidity and stiffness. Fixed sections of these tissues were evaluated for collagen and elastin content, and glandularity to assess fibrosis. Statistical analysis included the Student t test and calculation of Pearson correlation coefficients to compare groups.
RESULTS: Periurethral prostate tissues demonstrated nonlinear viscoelastic mechanical behavior. Tissue from men with lower urinary tract symptoms was significantly stiffer (p = 0.0016) with significantly higher collagen content (p = 0.0038) and lower glandularity than that from men without lower urinary tract symptoms (American Urological Association symptom index 8 or greater vs 7 or less).
CONCLUSIONS: Findings show that extracellular matrix deposition and fibrosis characterize the periurethral prostate tissue of some men with lower urinary tract symptoms. They point to fibrosis as a factor contributing to lower urinary tract symptom etiology.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22906651      PMCID: PMC3485634          DOI: 10.1016/j.juro.2012.06.007

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  29 in total

Review 1.  Molecular targets in pulmonary fibrosis: the myofibroblast in focus.

Authors:  Chris J Scotton; Rachel C Chambers
Journal:  Chest       Date:  2007-10       Impact factor: 9.410

2.  Stromal nodules in benign prostatic hyperplasia.

Authors:  E Bierhoff; J Vogel; M Benz; T Giefer; N Wernert; U Pfeifer
Journal:  Eur Urol       Date:  1996       Impact factor: 20.096

3.  Stress-strain characteristics of fresh and frozen human aortic and mitral leaflets and chordae tendineae. Implications for clinical use.

Authors:  R E Clark
Journal:  J Thorac Cardiovasc Surg       Date:  1973-08       Impact factor: 5.209

4.  Two-dimensional mechanical properties of rabbit skin. I. Experimental system.

Authors:  Y Lanir; Y C Fung
Journal:  J Biomech       Date:  1974-01       Impact factor: 2.712

5.  Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction.

Authors:  Debra E Irwin; Zoe S Kopp; Barnabie Agatep; Ian Milsom; Paul Abrams
Journal:  BJU Int       Date:  2011-01-13       Impact factor: 5.588

6.  Urologic diseases in America project: benign prostatic hyperplasia.

Authors:  John T Wei; Elizabeth Calhoun; Steven J Jacobsen
Journal:  J Urol       Date:  2005-04       Impact factor: 7.450

7.  Longitudinal association between prostatitis and development of benign prostatic hyperplasia.

Authors:  Jennifer L St Sauver; Debra J Jacobson; Michaela E McGree; Cynthia J Girman; Michael M Lieber; Steven J Jacobsen
Journal:  Urology       Date:  2008-03       Impact factor: 2.649

Review 8.  TGF-beta and fibrosis in different organs - molecular pathway imprints.

Authors:  Dirk Pohlers; Julia Brenmoehl; Ivonne Löffler; Cornelia K Müller; Carola Leipner; Stefan Schultze-Mosgau; Andreas Stallmach; Raimund W Kinne; Gunter Wolf
Journal:  Biochim Biophys Acta       Date:  2009-06-17

Review 9.  Intestinal fibrosis in IBD--a dynamic, multifactorial process.

Authors:  Florian Rieder; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-04       Impact factor: 46.802

10.  Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis.

Authors:  Grégoire Robert; Aurélien Descazeaud; Nathalie Nicolaïew; Stéphane Terry; Nanor Sirab; Francis Vacherot; Pascale Maillé; Yves Allory; Alexandre de la Taille
Journal:  Prostate       Date:  2009-12-01       Impact factor: 4.104

View more
  58 in total

1.  Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia.

Authors:  Petra Popovics; Wisam N Awadallah; Sarah E Kohrt; Thomas C Case; Nicole L Miller; Emily A Ricke; Wei Huang; Marisol Ramirez-Solano; Qi Liu; Chad M Vezina; Robert J Matusik; William A Ricke; Magdalena M Grabowska
Journal:  Prostate       Date:  2020-05-01       Impact factor: 4.104

2.  Uropathogenic Escherichia coli-induced fibrosis, leading to lower urinary tract symptoms, is associated with type 2 cytokine signaling.

Authors:  Ashlee Bell-Cohn; Daniel J Mazur; Christel Hall; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Am J Physiol Renal Physiol       Date:  2019-01-09

3.  Fluorescence of Picrosirius Red Multiplexed With Immunohistochemistry for the Quantitative Assessment of Collagen in Tissue Sections.

Authors:  Kyle A Wegner; Adib Keikhosravi; Kevin W Eliceiri; Chad M Vezina
Journal:  J Histochem Cytochem       Date:  2017-07-10       Impact factor: 2.479

4.  Histotripsy of the Prostate in a Canine Model: Characterization of Post-Therapy Inflammation and Fibrosis.

Authors:  Sarah E Darnell; Timothy L Hall; Scott A Tomlins; Xu Cheng; Kimberly A Ives; William W Roberts
Journal:  J Endourol       Date:  2015-02-18       Impact factor: 2.942

Review 5.  Targeting phenotypic heterogeneity in benign prostatic hyperplasia.

Authors:  Douglas W Strand; Daniel N Costa; Franto Francis; William A Ricke; Claus G Roehrborn
Journal:  Differentiation       Date:  2017-08-04       Impact factor: 3.880

6.  Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network.

Authors:  Opal Lin-Tsai; Peter E Clark; Nicole L Miller; Jay H Fowke; Omar Hameed; Simon W Hayward; Douglas W Strand
Journal:  Prostate       Date:  2014-02-05       Impact factor: 4.104

7.  The senescence-associated secretory phenotype promotes benign prostatic hyperplasia.

Authors:  Paz Vital; Patricia Castro; Susan Tsang; Michael Ittmann
Journal:  Am J Pathol       Date:  2014-01-13       Impact factor: 4.307

Review 8.  Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?

Authors:  Granville L Lloyd; Jeffrey M Marks; William A Ricke
Journal:  Curr Urol Rep       Date:  2019-08-03       Impact factor: 3.092

9.  Complex cellular composition of solitary fibrous tumor of the prostate.

Authors:  Mehrnaz Gharaee-Kermani; Rohit Mehra; Dan R Robinson; John T Wei; Jill A Macoska
Journal:  Am J Pathol       Date:  2014-01-13       Impact factor: 4.307

10.  Obesity-induced diabetes and lower urinary tract fibrosis promote urinary voiding dysfunction in a mouse model.

Authors:  Mehrnaz Gharaee-Kermani; Jose A Rodriguez-Nieves; Rohit Mehra; Chad A Vezina; Aruna V Sarma; Jill A Macoska
Journal:  Prostate       Date:  2013-03-26       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.